NCT04663464View on ClinicalTrials.gov

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

March 27, 2021

Study Completion Date

November 19, 2021

Conditions
Healthy Volunteers
Interventions
COMBINATION_PRODUCT

abaloparatide-sMTS

Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

COMBINATION_PRODUCT

abaloparatide-SC

Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen

Trial Locations (1)

45227

Medpace Clinical Pharmacology, Cincinnati

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Radius Health, Inc.

INDUSTRY